EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! - Älteste Beiträge zuerst (Seite 1119)
eröffnet am 29.01.04 09:28:54 von
neuester Beitrag 23.12.23 12:39:57 von
neuester Beitrag 23.12.23 12:39:57 von
Beiträge: 12.859
ID: 814.884
ID: 814.884
Aufrufe heute: 0
Gesamt: 1.588.479
Gesamt: 1.588.479
Aktive User: 0
ISIN: AU000000PVA7 · WKN: A0Q4DA
1,8250
EUR
-2,93 %
-0,0550 EUR
Letzter Kurs 03.05.18 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9000 | +305,04 | |
| 0,6500 | +25,75 | |
| 6,0000 | +25,00 | |
| 56,69 | +20,00 | |
| 0,6400 | +18,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,6000 | -12,16 | |
| 8,5000 | -15,00 | |
| 0,7300 | -18,59 | |
| 92,06 | -19,84 | |
| 2,7280 | -29,14 |
Feedback
Psivida stürzt ab und Alimera so gerade wieder im Plus.
Damit habe ich nicht gerechnet.
Damit habe ich nicht gerechnet.
psivida
alimera
Das Spielchen hat schon vor 2-3 Wochen begonnen. Der Kurs wird wieder gezielt nach unten geholt um Anleger dazu zu bringen aus Angst Ihre Aktien zu verkaufen, die dann munter eingesammelt werden, um beim nächsten Anstieg große Kasse zu machen. Schau Dir mal an wie der Kurs oft 100 Stück weise nach unten geht. Das gab es bei Psivida schon sehr oft. Die Kunst ist dabei mit zu schwimmen.
Man weiß jedoch nie, wann die Drehung nach oben kommt und dann geht es wieder sehr schnell.
Irgendwann geht einem beim Nachkauf das Geld aus und dann kann es durchaus sein, dass es noch einige Prozent nach unten geht.
Hoffentlich geht es nicht mehr allzuweit nach unten.
Man weiß jedoch nie, wann die Drehung nach oben kommt und dann geht es wieder sehr schnell.
Irgendwann geht einem beim Nachkauf das Geld aus und dann kann es durchaus sein, dass es noch einige Prozent nach unten geht.
Hoffentlich geht es nicht mehr allzuweit nach unten.
PSivida Corp. ’s ( PSDV ) share price has entered into oversold territory with an RSI value of 27.2. The Zacks Consensus Estimate for PSivida for the full year period has improved 1 cent over the past two months to -59 cents per share. Currently, PSivida has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( PSDV ) after its recent drop.
pSivida Corp. (PSDV) (PVA.AX), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida’s president and chief executive officer, Dr. Paul Ashton, will discuss pSivida’s Tethadur™ technology designed to provide sustained delivery of biologics at The World Ophthalmology Conference in Tokyo, April 2-6 and at the SMi Inaugural Conference on Biosimilars and Biobetters USA, in Iselin, New Jersey, April 7-8.
“More than half of the top selling drugs today are biologics. Unfortunately to be effective these drugs must be injected frequently as there is currently no approved technology to deliver most biologics on a sustained basis,” said Dr. Ashton. “We believe our Tethadur technology may provide a solution for sustained-release delivery of many of these molecules. We are pleased with our preclinical in vitro results to date and expect to report data from animal studies by the end of this summer.”
Tethadur utilizes an injectable, bioerodible, nanostructured, porous BioSilicon™ material for drug delivery. The size of the pores in the material is manufactured using nanotechnology to accommodate specific biologic molecules. “Tethadur is not an implant,” Dr. Ashton stated. “Rather, it is suspension of a powdery material and a solution of a biologic drug that is injected into the patient – either in the eye in ophthalmic indications or subcutaneously for other systemic indications—and is designed to deliver the biologic molecules on a sustained basis.”
Dr. Ashton’s presentation before the World Ophthalmology Congress 2014 will be recorded and published following the scientific session. His presentation, “Sustained Delivery of Proteins and Antibodies” will take place on Saturday April 5 from 8:30 a.m. to 10 a.m. (Tokyo time).
On Tuesday, April 8, at 11:30 am ET, Dr. Ashton will present “Biosimilars vs. Biobetters! Determining the Implications for Product Developers in the Pharmaceutical Industry” at the Biosimilars & Biobetters USA conference in New Jersey.
“More than half of the top selling drugs today are biologics. Unfortunately to be effective these drugs must be injected frequently as there is currently no approved technology to deliver most biologics on a sustained basis,” said Dr. Ashton. “We believe our Tethadur technology may provide a solution for sustained-release delivery of many of these molecules. We are pleased with our preclinical in vitro results to date and expect to report data from animal studies by the end of this summer.”
Tethadur utilizes an injectable, bioerodible, nanostructured, porous BioSilicon™ material for drug delivery. The size of the pores in the material is manufactured using nanotechnology to accommodate specific biologic molecules. “Tethadur is not an implant,” Dr. Ashton stated. “Rather, it is suspension of a powdery material and a solution of a biologic drug that is injected into the patient – either in the eye in ophthalmic indications or subcutaneously for other systemic indications—and is designed to deliver the biologic molecules on a sustained basis.”
Dr. Ashton’s presentation before the World Ophthalmology Congress 2014 will be recorded and published following the scientific session. His presentation, “Sustained Delivery of Proteins and Antibodies” will take place on Saturday April 5 from 8:30 a.m. to 10 a.m. (Tokyo time).
On Tuesday, April 8, at 11:30 am ET, Dr. Ashton will present “Biosimilars vs. Biobetters! Determining the Implications for Product Developers in the Pharmaceutical Industry” at the Biosimilars & Biobetters USA conference in New Jersey.
Trading Spotlight
WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (PSDV) (PVA.AX), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 for ILUVIEN® following the recent resubmission of the New Drug Application (NDA) by pSivida’s licensee, Alimera Sciences. The FDA acknowledged the resubmission as received as a complete class 2 response to the FDA’s October 2013 complete response letter.
The resubmission responded to questions raised in the FDA’s October 2013 letter and provided data from ILUVIEN patients and from physician experience with the applicator in the United Kingdom and Germany where ILUVIEN is currently commercially available.
“We are pleased to have the PDUFA goal date set for ILUVIEN and look forward to the FDA’s action on the resubmitted NDA,” said Paul Ashton, pSivida’s president and chief executive officer.
pSivida Corp. (PSDV) (PVA.AX), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 for ILUVIEN® following the recent resubmission of the New Drug Application (NDA) by pSivida’s licensee, Alimera Sciences. The FDA acknowledged the resubmission as received as a complete class 2 response to the FDA’s October 2013 complete response letter.
The resubmission responded to questions raised in the FDA’s October 2013 letter and provided data from ILUVIEN patients and from physician experience with the applicator in the United Kingdom and Germany where ILUVIEN is currently commercially available.
“We are pleased to have the PDUFA goal date set for ILUVIEN and look forward to the FDA’s action on the resubmitted NDA,” said Paul Ashton, pSivida’s president and chief executive officer.
http://investors.psivida.com/releasedetail.cfm?ReleaseID=841…" target="_blank" rel="nofollow ugc noopener">http://investors.psivida.com/releasedetail.cfm?ReleaseID=841…
Sorry, Link funktioniert leider nicht. News können auch auf der Homepage von Psivida angesehen werden.
oder einfach so:
April 23, 2014
pSivida Selected to Present at 2014 Opthalmology Innovation Summit
WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The Ophthalmology Innovation Summit (OIS), April 24, 2014 at the Seaport Hotel in Boston, MA. pSivida's president and chief executive officer, Dr. Paul Ashton, will discuss sustained delivery of antibodies and other large biologics with pSivida's Tethadur™ technology.
The OIS Summit, which held its first meeting 2009, serves as a forum to unite the leading clinicians, entrepreneurs, investors and industry executives to drive ophthalmic innovation (www.ophthalmologysummit.com).
"The introduction of antibody-based proteins targeting VEGF has transformed the treatment of age related macular degeneration and diabetic eye disease, the two biggest causes of vision loss in developed countries. These drugs, although effective, unfortunately must be injected directly into the eye every one to two months. This is a tremendous burden to patients," said Dr. Ashton. "Our Tethadur delivery system has the potential to provide sustained delivery of these drugs to significantly reduce the frequency of injections and improve efficacy."
pSivida's BioSilicon technology system utilizes a fully-erodible, honeycomb structure of nano-porous silicon to provide sustained delivery of therapeutics. Tethadur™, an application of BioSilicon technology, is designed to provide sustained delivery of large biologic molecules, including peptides, proteins and antibodies. Tethadur uses BioSilicon, a powdery, fully bioerodible, nanostructured, porous silicon, designed to provide sustained delivery of therapeutics. The pores in the BioSilicon are manufactured to accommodate specific biologic molecules. A suspension of BioSilicon and a biologic drug in solution is injected - either in the eye in ophthalmic indications or subcutaneously for other systemic indications. The erosion of the BioSilicon is designed to release the biologic molecules on a sustained basis.
April 23, 2014
pSivida Selected to Present at 2014 Opthalmology Innovation Summit
WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The Ophthalmology Innovation Summit (OIS), April 24, 2014 at the Seaport Hotel in Boston, MA. pSivida's president and chief executive officer, Dr. Paul Ashton, will discuss sustained delivery of antibodies and other large biologics with pSivida's Tethadur™ technology.
The OIS Summit, which held its first meeting 2009, serves as a forum to unite the leading clinicians, entrepreneurs, investors and industry executives to drive ophthalmic innovation (www.ophthalmologysummit.com).
"The introduction of antibody-based proteins targeting VEGF has transformed the treatment of age related macular degeneration and diabetic eye disease, the two biggest causes of vision loss in developed countries. These drugs, although effective, unfortunately must be injected directly into the eye every one to two months. This is a tremendous burden to patients," said Dr. Ashton. "Our Tethadur delivery system has the potential to provide sustained delivery of these drugs to significantly reduce the frequency of injections and improve efficacy."
pSivida's BioSilicon technology system utilizes a fully-erodible, honeycomb structure of nano-porous silicon to provide sustained delivery of therapeutics. Tethadur™, an application of BioSilicon technology, is designed to provide sustained delivery of large biologic molecules, including peptides, proteins and antibodies. Tethadur uses BioSilicon, a powdery, fully bioerodible, nanostructured, porous silicon, designed to provide sustained delivery of therapeutics. The pores in the BioSilicon are manufactured to accommodate specific biologic molecules. A suspension of BioSilicon and a biologic drug in solution is injected - either in the eye in ophthalmic indications or subcutaneously for other systemic indications. The erosion of the BioSilicon is designed to release the biologic molecules on a sustained basis.
Zitat von wuenschmirwas: http://investors.psivida.com/releasedetail.cfm?ReleaseID=841…
Nachdem Psivida,( Paul Ashton), TETHADUR auf der The World Ophthalmology Conference in Tokyo, April 2-6 und auf der SMi Inaugural Conference on Biosimilars and Biobetters USA, in Iselin, New Jersey, April 7-8, ausführlich vorgestellt hat
nun auch hier:
...today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The Ophthalmology Innovation Summit (OIS), April 24, 2014 at the Seaport Hotel in Boston, MA.
Fleissig sind sie ja, hoffentlich trägt es auch Früchte.
Der große Vorteil von Tethadur ist, dass es nach einer gewissen Zeit, komplett im/vom Körper abgebaut wird. Somit entfällt eine Entfernung durch den Operateur.
Dr. Ashton. "Our Tethadur delivery system has the potential to provide sustained delivery of these drugs to significantly reduce the frequency of injections and improve efficacy."
pSivida's BioSilicon technology system utilizes a fully-erodible, honeycomb structure of nano-porous silicon to provide sustained delivery of therapeutics. Tethadur™, an application of BioSilicon technology, is designed to provide sustained delivery of large biologic molecules, including peptides, proteins and antibodies. Tethadur uses BioSilicon, a powdery, fully bioerodible, nanostructured, porous silicon, designed to provide sustained delivery of therapeutics. The pores in the BioSilicon are manufactured to accommodate specific biologic molecules. A suspension of BioSilicon and a biologic drug in solution is injected - either in the eye in ophthalmic indications or subcutaneously for other systemic indications. The erosion of the BioSilicon is designed to release the biologic molecules on a sustained basis.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| +3,18 | |
| +1,02 | |
| 0,00 | |
| +53,85 | |
| +2,80 | |
| -0,06 | |
| -12,37 | |
| +0,29 | |
| +3,08 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 215 | ||
| 90 | ||
| 78 | ||
| 58 | ||
| 56 | ||
| 34 | ||
| 34 | ||
| 29 | ||
| 27 | ||
| 25 |
